Although HMG-CoA reductase inhibitors are considered generally safe in early CKD, there are differences in their pharmacokinetic properties that might determine the choice of a particular statin in advanced CKD or in end-stage renal disease. The gene discussed is HMGCR; the disease is stage 5 chronic kidney disease.